{"id":"W4400998846","doi":"10.1186/s12885-023-11316-0","title":"Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study","year":2024,"lang":"en","type":"article","venue":"BMC Cancer","topic":"Tryptophan and brain disorders","field":"Neuroscience","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; Hôtel-Dieu de Québec","funders":"Merck Sharp and Dohme; Astellas Pharma; Eisai; Incyte; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Pembrolizumab; Medicine; Tolerability; Head and neck squamous-cell carcinoma; Oncology; Clinical endpoint; Internal medicine; Regimen; Phases of clinical research; Clinical trial; Ipilimumab; Adverse effect; Head and neck cancer; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002232252,0.001172304,0.001900049,0.000387066,0.0004333559,0.0008782587,0.0007868441,0.001271491,0.004480227],"category_scores_gemma":[0.0009179285,0.0006059804,0.001796406,0.0003719944,0.0008133337,0.001190694,0.0002961829,0.00280036,0.0009585625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008364003,"about_ca_system_score_gemma":0.001264552,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009709246,"about_ca_topic_score_gemma":0.002958513,"domain_scores_codex":[0.999531,0.0002236716,0.00003251689,0.0000826246,0.00004840223,0.00008175644],"domain_scores_gemma":[0.9993062,0.0001593933,0.0001683354,0.00005738893,0.00005416185,0.0002544879],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9368524,0.02621598,0.001844668,0.0008395827,0.001083799,0.00008807755,0.00009596618,0.0005110697,0.007301701,0.00008729059,0.001175738,0.0239038],"study_design_scores_gemma":[0.8322408,0.1616888,0.003837738,0.00003023547,0.0005075561,0.00006742249,0.00002765517,0.0003859416,0.0005255022,0.00007797194,0.000594663,0.00001569384],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922909,0.002642215,0.0002364889,0.000323345,0.0001864128,0.002253514,0.0006293374,0.00006993399,0.001367835],"genre_scores_gemma":[0.9924165,0.00161128,0.0008530616,0.0009374228,0.0002441703,0.001848724,0.0007603879,0.0000139019,0.001314482],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004480227,"threshold_uncertainty_score":0.01498783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04522785211261003,"score_gpt":0.3353546691208892,"score_spread":0.2901268170082791,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}